Locus Cell Co

Locus Cell Co Diluted EPS

The Diluted Earnings per Share of Locus Cell Co (6891.TWO) as of Oct 15, 2026 is -0.57 TWD. In the previous year, Diluted Earnings per Share was -0.48 TWD — a change of 16.64% (lower).

Diluted EPS

-0.57TWD

YoY

16.64%

Last updated:

Diluted Earnings per Share of Locus Cell Co is 2024 -0.57 TWD. Diluted Earnings per Share of Locus Cell Co was 2023 -0.48 TWD. It decreases by 16.64% lower compared to the previous year.

The Locus Cell Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2020
0.00 TWD
Jan 1, 2021
-0.17 TWD
Jan 1, 2022
-0.27 TWD
Jan 1, 2023
-0.48 TWD
Jan 1, 2024
-0.57 TWD
The Locus Cell Co Diluted EPS history
YEARDiluted EPSYoY
-0.57TWD+16.64%
-0.48TWD+79.44%
-0.27TWD+58.82%
-0.17TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

Diluted Earnings per Share of Locus Cell Co is -0.57 TWD in 2024.

Diluted Earnings per Share of Locus Cell Co changed from -0.48 TWD to -0.57 TWD, representing a 16.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Locus Cell Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Locus Cell Co